An earnings triple play is a stock that reports earnings and manages to 1) beat analyst EPS estimates, 2) beat analyst sales estimates, and 3) raise forward guidance.  You can read more about “triple plays” at Investopedia.com where they’ve given Bespoke credit for popularizing the term.  We like triple plays as an indication that a company’s business is firing on all cylinders, with better-than-expected results and an improving outlook.  A triple play is indicative of positive “fundamental momentum” instead of pure fundamentals, and there are always plenty of names with both high and low valuations on our quarterly list.

Bespoke’s Triple Play Report highlights companies that have recently reported earnings triple plays, and it features commentary from management on triple-play conference calls, company descriptions and analysis, and price charts.  Bespoke’s Triple Play Report is available at the Bespoke Institutional level only.  You can sign up for Bespoke Institutional now and receive a 14-day trial to read this week’s Triple Play Report, which features 20 new stocks.  To sign up, choose either the monthly or annual checkout link below:

Bespoke Institutional – Monthly Payment Plan

Bespoke Institutional – Annual Payment Plan

CareDx (CDNA), a healthcare name that specializes in transplant patient care, is an example of a company that recently reported an earnings triple play. The stock started the year off slow but has flown higher by more than 250% since April lows. CDNA has put together back-to-back triple plays, garnering one-day earnings reaction gains of 34.1% and 18%.

Looking at the snapshot below from our Earnings Explorer, CDNA has started a bit of a run on the earnings front after some weaker reports in 2022 and 2023. The past year of earnings has painted a much rosier picture of the company, as the stock has moved at least 9.5% higher on each of its post-earnings trading days. In the three years prior to the last four earnings reports, the average one-day move for the stock was a decline of 5.1% post earnings. On its last four reports, it has seen an average swing higher of 18.9%.

The company’s core offerings include AlloSure Kidney and AlloMap Heart, non-invasive blood tests designed to monitor the health of organ transplant recipients. AlloSure measures donor-derived cell-free DNA (dd-cfDNA) to detect signs of organ rejection, while AlloMap assesses gene expression profiles to evaluate heart transplant rejection risk. AlloSeq is a suite of next-generation sequencing (NGS) solutions that are essential for matching donors and recipients and monitoring engraftment success in transplant patients. These tests are obviously important, and they are performing quite well for CDNA. You can read more about CDNA and the 19 other triple plays in our newest report by starting a Bespoke Institutional trial today.

Bespoke Investment Group, LLC believes all information contained in these reports to be accurate, but we do not guarantee its accuracy. None of the information in these reports or any opinions expressed constitutes a solicitation of the purchase or sale of any securities or commodities. This is not personalized advice. Investors should do their own research and/or work with an investment professional when making portfolio decisions. As always, past performance of any investment is not a guarantee of future results. Bespoke representatives or clients may have positions in securities discussed or mentioned in its published content.